07:00 , May 11, 2015 |  BC Week In Review  |  Clinical News

NOxCF regulatory update

The European Commission granted Orphan Drug designation to AIT’s AIT-CF to treat cystic fibrosis (CF). The inhaled nitric oxide formulation using the company’s drug delivery system has completed a Phase IIa trial in adults with...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Clinical News

NOxCureCF: Phase II started

Advanced Inhalation Therapies began an open-label, Israeli Phase II trial to evaluate NOxCureCF in CF patients ages >=10 years. Advanced Inhalation Therapies Ltd. , Rehovot, Israel   Product: NOxCureCF   Business: Pulmonary   Molecular target:...